Exploring Uropathogenic Bacteria and Measuring Serum IL-34 and IL-35 Levels in Women Affected by Systemic Lupus Erythematosus
Article Sidebar
Main Article Content
Abstract
Systemic lupus erythematosus is an autoimmune disease occurs when the immune system mistakes self-tissue for foreign antigens, it causes organ tissue destruction in Systemic lupus erythematosus risk factors include interleukin biomarkers and urinary tract infections. The goal of this study was to identify uropathogenic bacteria in systemic lupus erythematosus patients, which is essential for avoiding serious complications. Additionally, serum levels of interleukin -34 and interleukin-35 in Systemic lupus erythematosus patients serve as a predictor biomarkers for systemic lupus erythematosus diagnosis. 65 women with systemic lupus erythematosus compare to 50 healthy controls were included in this study. Isolation and identification of uropathogenic bacteria , and use enzyme-linked immunosorbent assays to check serum levels of interleukin-34 and interleukin-35.The results revealed that E. coli accounted for 70% of the uropathogenic bacteria identified, with Proteus spp. come in second accounted 20% followed by Klebsiella spp. accounted 6%., while Enterococcus fecalis and Enterobacter spp. accounted for 2% with each. A notable rise in serum levels of IL-34 and IL-35 was observed when comparing patients with systemic lupus erythematosus illness to controls, with a P.value of less than 0.05.This study investigated that E. coli was the most frequently occurring of uropathogenic bacteria and showed higher serum levels of interleukin IL-34 and IL-35 in women with systemic lupus erythematosus.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Herrada, A.A., Escobedo N., Iruretagoyena, M., Valenzuela, R.A, Burgos, P.I, Cuitino L, Llanos C. (2019).Innate Immune Cells' Contribution to Systemic Lupus Erythematosus. Front Immunol. 15;10:772. doi: 10.3389/fimmu.2019.00772.
Vincent, F.B, Morand, E.F., Mackay, F.(2012). BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol Cell Biol; 90:293-303.
Pan, L, Lu M.P, Wang, J.H, Xu. M., Yang,S.R.(2020). Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr;16(1):19-30. doi: 10.1007/s12519-019-00229-3.
Harrington, L.E., Hatton,R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., Weaver, C.T.(2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol; 6:1123-1132.
Jacob, N., Yang, H., Pricop, L., Liu, Y., Gao, X., Zheng, S.G., Wang, J., Gao, H.X., Putterman, C., Koss, M.N., Stohl,W., Jacob,C.O.,(2009). Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol; 182:2532-2541.
Wang, H., Cao, J., Lai, X. (2016).Serum Interleukin-34 Levels Are Elevated in Patients with Systemic Lupus Erythematosus. Molecules. 28;22(1):35.
doi: 10.3390/molecules22010035.
7. Lin, H., Lee, E., Hestir, K., Leo, C., Huang, M., Bosch, E., Halenbeck R., Wu G., Zhou, A., Behrens,D. et al.(2008). Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science;320:807–811. doi: 10.1126/science.1154370.
8. Chen, Z., Buki, K., Vaaraniemi,J., Gu, G., Vaananen, H.K.(2011). The critical role of IL-34 in osteoclastogenesis. PLoS ONE.;6:e18689. doi: 10.1371/journal.pone.0018689.
9.Chang, E.J., Lee, S.K., Song, Y.S., Jang, Y.J., Park, H.S., Hong, J.P., Ko, A.R., Kim, D.Y., Kim, J.H., Lee, Y.J., et al. (2014).IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J. Clin. Endocrinol. Metab. ;99:E1263–E1271. doi: 10.1210/jc.2013-4409.
10.Masteller, E.L., Wong, B.R(2014). Targeting IL-34 in chronic inflammation. Drug Discov. Today. 19:1212–1216. doi:10.1016/j.drudis.2014.05.016.
11.Ye C, Yano H, Workman CJ, Vignali DAA. (2021).Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases. J Interferon Cytokine Res. Nov;41(11):391-406. doi: 10.1089/jir.2021.0147.
12.Bahadorian,D., Tola, A.,Faraj, T.A., Kheder, R.K., Soran , K .Najmaldin, S.K.,Dariush Haghmorad,D., Samaneh mollazadeh,S., Seyed-Alireza Esmaeili,A.E.,(2024).A glance on the role of IL-35 in systemic lupus erythematosus (SLE).Cytokine.Volume 176,April .156501
13.Petri, M., Orabi, A, Alarcon, G., Gordon, C., Merrill, J., Fortin, P. et al.(2012).Derivation and validation of systemic lupus international collaboration clinic classification criteria for systemic lupu eryth Rheumatol ; 64 (8): 2677-2686.
14.Amador-Patarroyo, MJ., Rodriguez-Rodriguez, A., Montoya-Ortiz, G. (2012).How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis. ;2012:251730. doi: 10.1155/2012/251730.
15.Doria, A., Sarzi-Puttini, P., Shoenfeld, Y.(2008).Infections, rheumatism and autoimmunity:the conflicting relationship between humans and their environment. Autoimmun Rev ,8:1-4.
16.Doria, A., Zampieri ,S., Sarzi-Puttini, P.(2008).Exploring the complex relationship between infections and autoimmunity. Autoimmun.Rev ; 8:89-91.
17.Mountz, JD., Wang, JH., Xie, S., Hsu, HC.(2011). Cytokine regulation of B-cell migratory behavior favors formation of germinal centers in autoimmune disease. Discov Med ;11: 76–85.
18.Grondal,G.I.,Gunnarsson, J., Ronnelid, S.,Rogberg, L., Klareskog, and I. Lundberg,(2000).“Cytokine production, serum levels and disease activity in systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 18, no. 5, pp. 565–570.
19. Amador-Patarroyo, MJ., Rodriguez-Rodriguez, A., Montoya-Ortiz, G.(2012). How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis;251730. doi: 10.1155/2012/251730.
20.Hidalgo-Tenorio, C., Jiménez-Alonso, J., de Dios Luna, J., Tallada, M., Martínez-Brocal, A., Sabio, JM.(2004). Virgen de las Nieves Lupus Research Group. Urinary tract infections and lupus erythematosus. Ann Rheum Dis. Apr;63(4):431-7. doi:10.1136/ard.2003.006346.
21. Malek TR.(2003) The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol; 74:961-5.
22. Wang, H., Cao, J., Lai, X.(2016).Serum Interleukin-34 Levels Are Elevated in Patients with Systemic Lupus Erythematosus. Molecules. 28;22(1):35. doi:10.3390/molecules22010035.
23.El-Gawish,H., M., Mohamed Sharaf, D., Raafat Abdel-Fattah, N., Abdelaziz Rashed, S. (2019). 'Evaluation of serum interleukin-34, as a marker of disease activity in systemic lupus erythematosus and rheumatoid arthritis patients, Zagazig University Medical Journal, 25(3), pp. 285-290. doi 10.21608/ZUMJ.2019.7209.1021
24.Xie, HH., Shen, H., Zhang, L., Cui, MY., Xia, LP., Lu, J.(2018). Elevated Serum Interleukin-34 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity. Sci Rep. 22;8(1):3462. doi: 10.1038/s41598-018-21859-z.
25.Chang, S., Choi,B., Choi, J., Yoo, J., Ha, Y., Cho H et al. Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis. Rheumatol Int 2015; 35 (1): 71– 79.
26.Lelios, I., Cansever, D., Utz, SG., Mildenberger, W., Stifter, SA., Greter, M.(2020). Emerging roles of IL-34 in health and disease. J Exp Med. 2;217(3):e20190290. doi:10.1084/jem.20190290
27.Shen, P., Roch, T., Lampropoul, V., et al.(2014). IL35 producing B cells are critical regulators of immunity during autoimmune and infec tious diseases. Nature;567:366–370. doi:10.1038/nature1 2979
28.Wang, R-X., Yu, C-R., Dambeza, IM., et al.(2014) Interleukin-35 induces regulatory B-cells that suppress autoimmune disease. Nat Med;20:633–641. doi:10.1038/nm.3554 37.